Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.36 |
| ▸ | MLYCD | O95822 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | GCG | P01275 | 5/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036397 | 0.91 | GCGR (0.36) | GCGRMLYCDHRH3GCGHDAC4 | |
| SCHEMBL6035849 | 0.89 | MLYCD (0.36) | GCGRMLYCDGCGHDAC4CNR1 | |
| SCHEMBL6036332 | 0.89 | GCGR (0.36) | GCGRMLYCDHRH3GCGHDAC4 | |
| SCHEMBL6036236 | 0.87 | MLYCD (0.35) | GCGRMLYCDGCGHDAC4CNR1 | |
| SCHEMBL6036211 | 0.86 | GCG (0.35) | GCGRMLYCDHRH3GCGACACB | |
| SCHEMBL6035279 | 0.83 | GCGR (0.37) | GCGRMLYCDHRH3GCGHDAC4 | |
| SCHEMBL6035517 | 0.82 | FFAR4 (0.38) | GCGRSMN1; SMN2LTB4R | |
| SCHEMBL6035628 | 0.81 | GCGR (0.37) | GCGRMLYCDHRH3GCGACACB | |
| SCHEMBL6034481 | 0.80 | FFAR1 (0.43) | GCGRGCGL3MBTL1 | |
| SCHEMBL6035886 | 0.80 | FFAR4 (0.45) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | GCGR 93/4885MLYCD 962/4885HRH3 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.